📊 CDIOW Key Takeaways
Investment Thesis
Cardio Diagnostics is in critical financial distress with near-zero revenue generation ($14.8K), massive operating losses (-$6.5M), and zero cash reserves despite $7.8M in total assets. The company is burning cash rapidly with negative free cash flow of -$5.9M, indicating it is not operationally viable and faces imminent liquidity crisis without immediate capital infusion.
CDIOW Strengths
- Low debt burden with 0.00x debt-to-equity ratio indicating no financial leverage risk
- High current and quick ratios (9.79x) suggest sufficient short-term liquid assets relative to current liabilities
- Modest liabilities of $793.1K represent only 10.1% of total assets
CDIOW Risks
- Revenue collapse of 57.5% YoY with only $14.8K in latest period indicating complete commercial failure
- Zero cash and equivalents with -$5.9M free cash flow burn rate means company has weeks to months of runway remaining
- Net loss of $6.5M per period on negligible revenue results in unsustainable -43,832.5% net margin and -83.7% ROA
- Negative operating cash flow of -$5.7M indicates core business operations are destroying rather than generating value
- Severely diluted shareholder equity with -3.71 diluted EPS and -93.2% ROE showing persistent value destruction
Key Metrics to Watch
- Cash burn rate and remaining runway before insolvency
- Whether company achieves any meaningful revenue growth or secures capital infusion
- Operating expense reduction and path to cash flow breakeven
CDIOW Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.79x current ratio provides a solid financial cushion.
CDIOW Profitability Ratios
CDIOW vs Default Sector
How Cardio Diagnostics Holdings, Inc. compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CDIOW Balance Sheet & Liquidity
CDIOW 5-Year Financial Trend
5-Year Trend Summary: Cardio Diagnostics Holdings, Inc.'s revenue has grown significantly by 3,573% over the 5-year period, indicating strong business expansion. The most recent EPS of $-9.35 indicates the company is currently unprofitable.
CDIOW Growth Metrics (YoY)
CDIOW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.9K | -$1.4M | $-0.98 |
| Q2 2025 | $7.5K | -$1.3M | $-0.97 |
| Q1 2025 | $940 | -$1.6M | $-0.97 |
| Q3 2024 | $6.6K | -$1.4M | $-0.06 |
| Q2 2024 | $1.7K | -$1.3M | $-0.06 |
| Q1 2024 | $15.9K | -$1.0M | $-0.11 |
| Q3 2023 | N/A | -$290.1K | $-0.16 |
| Q2 2023 | N/A | -$290.1K | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CDIOW Capital Allocation
CDIOW SEC Filings
Access official SEC EDGAR filings for Cardio Diagnostics Holdings, Inc. (CIK: 0001870144)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CDIOW
What is the AI rating for CDIOW?
Cardio Diagnostics Holdings, Inc. (CDIOW) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CDIOW's key strengths?
Low debt burden with 0.00x debt-to-equity ratio indicating no financial leverage risk. High current and quick ratios (9.79x) suggest sufficient short-term liquid assets relative to current liabilities.
What are the risks of investing in CDIOW?
Revenue collapse of 57.5% YoY with only $14.8K in latest period indicating complete commercial failure. Zero cash and equivalents with -$5.9M free cash flow burn rate means company has weeks to months of runway remaining.
What is CDIOW's revenue and growth?
Cardio Diagnostics Holdings, Inc. reported revenue of $14.8K.
Does CDIOW pay dividends?
Cardio Diagnostics Holdings, Inc. does not currently pay dividends.
Where can I find CDIOW SEC filings?
Official SEC filings for Cardio Diagnostics Holdings, Inc. (CIK: 0001870144) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CDIOW's EPS?
Cardio Diagnostics Holdings, Inc. has a diluted EPS of $-3.71.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.